Literature DB >> 28159709

Role of the plasma cascade systems in ischemia/reperfusion injury of bone.

Shengye Zhang1, Carlos Wotzkow2, Anjan K Bongoni3, Jane Shaw-Boden2, Mark Siegrist2, Adriano Taddeo4, Fabian Blank5, Willy Hofstetter2, Robert Rieben6.   

Abstract

Ischemia/reperfusion (I/R) injury has been extensively studied in organs such as heart, brain, liver, kidney, and lung. As a vascularized organ, bone is known to be susceptible to I/R injury too, but the respective mechanisms are not well understood to date. We therefore hypothesized that, similar to other organs, plasma cascade-induced inflammation also plays a role in bone I/R injury. Reperfusion injury in rat tibia was induced by unilateral clamping of the femoral artery and additional use of a tourniquet, while keeping the femoral vein patent to prevent venous congestion. Rats were subjected to 4h ischemia and 24h reperfusion. Deposition of complement fragment C3b/c and fibrin as well as expression of tissue factor (TF), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and E-selectin was detected by immunohistochemistry. In plasma, the levels of high mobility group box1 (HMGB1) were measured by ELISA. The total level of complement in serum was assessed by the CH50 test. Our results show that deposition of C3b/c was significantly increased with respect to healthy controls in cortical bone as well as in marrow of reperfused limbs. C3b/c deposition was also increased in cortical bone, but not in bone marrow, of contralateral limbs. Deposition of fibrin, as well as expression of PAI-1, was significantly increased in bone after ischemia and reperfusion, whereas expression of tPA was reduced. These differences were most prominent in vessels of bone, both in marrow and cortical bone, and both in reperfused and contralateral limbs. However, PAI-1, was only increased in vessels of reperfused cortical bone and there were no significant changes in expression of E-selectin. With respect to solid bone tissue, a significant increase of C3b/c and fibrin deposition was shown in osteocytes, and for fibrin also in the bone matrix, in both contralateral and reperfused cortical bone compared with normal healthy controls. A slight expression of TF was visible in osteocytes of the normal healthy control group, while TF was not present in the experimental groups. Moreover, CH50 values in serum decreased over time and HMGB1 was significantly increased in plasma of animals at the end of reperfusion. We conclude that ischemia and reperfusion of bone leads to activation of the complement and coagulation systems and a downregulation of the fibrinolytic cascade. In the acute phase, a vascular inflammation induced by activation of the plasma cascade systems also occurs in the bone. This is similar to I/R injury of other vascularized organs and tissues.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone; Coagulation; Complement; Fibrinolysis; Ischemia/reperfusion injury

Mesh:

Substances:

Year:  2017        PMID: 28159709     DOI: 10.1016/j.bone.2016.12.007

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  3 in total

1.  Synergetic protective effect of remote ischemic preconditioning and prolyl 4‑hydroxylase inhibition in ischemic cardiac injury.

Authors:  Juesheng Yang; Jiajun Xu; Lei Tao; Shiyong Wang; Haiyan Xiang; Yanhua Tang
Journal:  Mol Med Rep       Date:  2022-01-14       Impact factor: 2.952

2.  Comparison of two different biomaterials in the bone regeneration (15, 30 and 60 days) of critical defects in rats.

Authors:  Patricia Brassolatti; Paulo Sérgio Bossini; Ana Laura Martins de Andrade; Genoveva Lourdes Flores Luna; Juliana Virginio da Silva; Luciana Almeida-Lopes; Marcos Aurélio Napolitano; Lucimar Retto da Silva de Avó; Ângela Merice de Oliveira Leal; Fernanda de Freitas Anibal
Journal:  Acta Cir Bras       Date:  2021-07-19       Impact factor: 1.388

Review 3.  High-Mobility Group Box-1 and Liver Disease.

Authors:  Harriet Gaskell; Xiaodong Ge; Natalia Nieto
Journal:  Hepatol Commun       Date:  2018-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.